Ophthalmic device having therapeutic agent delivery capability and method of forming same

Patent metadata

Field	Value
Publication number	US-9233069-B2
Application number	US-50555809-A
Country	US
Kind code	B2
Filing date	Jul 20, 2009
Priority date	Jul 21, 2008
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material.

First claim

We claim:

1. An ophthalmic device, comprising;
a mass of material, the mass of material being an acrylic material, the mass of material including at least 70% by weight hydrophobic acrylate and the hydrophobic acrylate being formed of at least 90% by weight of one or more monomers selected from the group consisting of 2-phenyl ethyl acrylate (PEA) and 2-phenyl ethyl methacrylate (PEMA); and
therapeutic agent disposed upon a peripheral surface of the mass of material wherein the therapeutic agent is hydrophobic and has a PC Log P that is at least 1.6 and wherein the therapeutic agent consists of an ophthalmic drug that consists of an anti-inflammatory, an anti-proliferative or a combination thereof;
wherein the mass of material is configured for insertion into an eye of a human and wherein attraction of the therapeutic agent to the hydrophobic acrylate controls sustained release of the therapeutic agent such that less than 50% by weight of the therapeutic agent is released from the mass of material in a period that is at least one week when the mass is submerged in basic salt solution and wherein the mass of material, the device and the therapeutic agent are free of any amino acid.

2. An ophthalmic device as in claim 1 wherein the therapeutic agent has a PC Log P that is at least 2.0.

3. An ophthalmic device as in claim 1 wherein the hydrophobic acrylate is entirely 2-phenyl ethyl methacrylate.

4. An ophthalmic device as in claim 1 wherein the acrylic material includes a substantial portion of hydrophilic acrylate.

5. An ophthalmic device as in claim 4 wherein the hydrophilic acrylate includes 2-hydroxyethylmethacrylate.

6. An ophthalmic device as in claim 4 wherein the mass of material releases a controlled amount of therapeutic agent when submerged in basic salt solution and wherein the hydrophobic acrylate and the hydrophilic acrylate are present in the mass of material in amounts such that the controlled amount of therapeutic agent is less than 60% of the total therapeutic agent in a time period that is at least 5 days.

7. An ophthalmic device as in claim 4 wherein the amount of hydrophilic acrylate and hydrophobic acrylate are selected to provide a predetermined release profile for the therapeutic agent.

8. An ophthalmic device as in claim 1 wherein the therapeutic agent is an anti-inflammatory agent.

9. An ophthalmic device as in claim 8 wherein the anti-inflammatory agent is nepafenac.

10. An ophthalmic device as in claim 1 wherein the mass of material is an intraocular lens selected from an Aphakic intraocular lens, an anterior Phakic intraocular lens and a posterior chamber Phakic intraocular lens.

11. An ophthalmic device as in claim 1 wherein the mass of material is a haptic of an intraocular lens.

12. An ophthalmic device as in claim 1 wherein the mass of material is located at least partially within an eye of an individual.

13. An ophthalmic device as in claim 1 wherein the mass of material is configured as part or the whole of an intraocular lens, a haptic of an intraocular lens or a separate piece that is inserted in the eye with or without an intraocular lens.

14. An ophthalmic device as in claim 1 wherein the mass of material releases a controlled amount of therapeutic agent when submerged in basic salt solution.

15. An ophthalmic device as in claim 14 wherein less than 50% by weight of the therapeutic agent is released from the ophthalmic device in the basic salt solution over a period that is at least one week.

16. An ophthalmic device consisting essentially of:
a mass of material, the mass of material being formed of components that consist essentially of acrylic material, cross-linking agent, colored dye and UV absorbing material wherein the acrylic material includes at least 70% by weight hydrophobic acrylate and the hydrophobic acrylate being formed of at least 90% by weight of one or more monomers selected from the group consisting of 2-phenyl ethyl acrylate and 2-phenyl ethyl methacrylate; and
therapeutic agent disposed upon a peripheral surface of the mass of material wherein the therapeutic agent is hydrophobic and has a PC Log P that is at least 1.0 and wherein the therapeutic agent consists of an ophthalmic drug that consists of an anti-inflammatory, an anti-proliferative or a combination thereof;
wherein the mass of material is configured for insertion into an eye of a human and wherein attraction of the therapeutic agent to the hydrophobic acrylate controls sustained release of the therapeutic agent such that less than 80% by weight of the therapeutic agent is released from the mass of material over a period that is at least three days when the mass is submerged in basic salt solution.

17. An ophthalmic device as in claim 16 wherein the therapeutic agent has a PC Log P that is at least 2.0.

18. An ophthalmic device as in claim 16 wherein the hydrophobic acrylate is entirely 2-phenyl ethyl methacrylate.

19. An ophthalmic device as in claim 16 wherein the therapeutic agent is an anti-inflammatory agent.

20. An ophthalmic device as in claim 16 wherein the mass of material is an intraocular lens selected from an Aphakic intraocular lens, an anterior Phakic intraocular lens and a posterior chamber Phakic intraocular lens.

21. An ophthalmic device as in claim 16 wherein the mass of material is a haptic of an intraocular lens.

22. An ophthalmic device as in claim 16 wherein the mass of material is located at least partially within an eye of an individual.

23. An ophthalmic device as in claim 16 wherein the therapeutic agent has a PC Log P that is at least 1.6 and wherein the attraction of the therapeutic agent to the hydrophobic acrylate provides for sustained release of the therapeutic agent such that less than 50% by weight of the therapeutic agent is released from the mass of material in a period that is at least one week.

Assignees

• Thomas Brett E
• Van Noy Stephen J
• Tsai Chi-Chun
• Novartis Ag

Inventors

• Thomas Brett E
• Van Noy Stephen J
• Tsai Chi-Chun

Classifications

• A61K31/165

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K9/0051 Primary

  Ocular inserts or implants · CPC title

• A61K31/195

  having an amino group · CPC title